Michael Earl
Director, Pharmaceutical Services

Is this your profile?

About

Michael Earl joined Owen Mumford as Director of Pharmaceutical Services in November 2020. He was previously the Commercial Vice-President at Bespak (now part of Recipharm), leading the commercial team there to drive growth in its substantial medical devices business. Prior to that, he worked for a number of pharma, biotech and device companies. In a career spanning 35 years, Mr Earl has been responsible for all aspects and stages of drug and device development and commercialisation. He has also completed a substantial number of commercial, licensing and mergers and acquisitions transactions.

Contributions

CONQUERING THE CHALLENGES OF CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT

Michael Earl discusses the factors that need to be taken into account for successful connected drug delivery device development.

More contributions

AREAS TO WATCH IN CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT

Michael Earl identifies areas of development in the field of connected drug delivery devices, providing an insight into what can be expected in the coming years. He draws on Owen Mumford’s own research, as well as discussions with industry experts and counterparts.

#134_2022_Jun_Owen_Mumford_featured

SUPPORTING PATIENTS ON THE ROAD TO SELF-CARE

Michael Earl discusses the importance of transitioning current healthcare models to embrace patient self-management and how advanced drug delivery device technologies, such as connectivity, can ease this burden on overstretched healthcare services.

A CHECKLIST FOR AUTOINJECTOR DESIGN

Michael Earl outlines the five key questions autoinjector designers typically ask during the development process and the choices available for tailoring autoinjector products.

#133_May_2022_OM_Fig2

INTERVIEW: STEVEN KAUFMAN, STEVANATO GROUP, & MICHAEL EARL, OWEN MUMFORD

In this exclusive interview, Steven Kaufman of Stevanato Group, and Michael Earl of Owen Mumford, talked with us about their companies' recent major agreement for the manufacturing and provision of prefillable syringes for the advanced two-step, single-use autoinjector, Aidaptus^®.

SO FAR SO GOOD: MAINTAINING THE MOMENTUM OF PROGRESS FOR SUSTAINABLE POLICIES

Michael Earl discusses the highlights of a review undertaken by Owen Mumford into how the pharmaceutical industry is faring on environmental, social and governance standards, noting that while the industry is performing above average overall, there remain some key areas for improvement.

AIDAPTUS^®: OWEN MUMFORD INTRODUCES ITS NEXT-GENERATION PLATFORM AUTOINJECTOR

Michael Earl introduces the next-generation Aidaptus^® autoinjector, explaining how this latest platform device from Owen Mumford can contribute to a faster speed-to-market, increased flexibility during drug development and improved patient outcomes.

Top